Recordati Rare Diseases Canada launched

Recordati, a global biopharmaceutical company committed to providing orphan therapies to underserved rare disease communities, today announced the incorporation of its Canadian affiliate, Recordati Rare Diseases Canada Inc.

Recordati Rare Diseases Canada, a company wholly-owned by the Italy-based Recordati Group (REC: MI), will be the exclusive provider of several treatments, including Carbaglu (carglumic acid), Cystadane (betaine anhydrous) and Cosmegen (dactinomycin) in Canada.

"We're thrilled to be a part of Canada's innovative biopharmaceutical community focused on bringing treatments to ultra-rare disease and oncology patients," said Paul McCabe, general manager, Recordati Rare Diseases Canada, "adding: As a company, we're happy to be able to bring these products together under one umbrella to offer the highest-quality treatments to these patients."